英国医用大麻注册:对的临床结果分析
Isaac Cowley1, Simon Erridge1,2, Arushika Aggarwal1
1Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.
Brain and behavior
|April 18, 2025
概括
基于大麻的药物改善了患者的生活质量. 这些产品耐受性良好,不良事件很少,这表明潜在的治疗益处.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 患者报告的结果
背景情况:
- 影响着数以百万计的人,其中很大一部分对传统治疗没有反应.
- 基于大麻的药物 (CBMP) 显示了对耐火性的治疗潜力.
- 关于CBMPs在管理中的有效性和安全性的高质量数据有限.
研究的目的:
- 评估CBMPs对特异性和一般健康相关生活质量 (HRQoL) 的影响.
- 评估使用CBMPs治疗耐药性患者患者患者报告结果指标 (PROM) 的变化.
主要方法:
- 来自英国医用大麻登记处的134名患者的病例系列分析.
- 在基线和1,3,6个月内评估包括QOLIE-31,SQS,EQ-5D-5L,GAD-7和PGIC在内的PROM.
- 根据严重程度收集和分类不良事件 (AE).
主要成果:
- 从基线到六个月的QOLIE-31和所有HRQoL PROM中观察到显著改善 (p <0.050).
- 29.85%的患者报告说,在六个月后,QOLIE-31的临床重要差异很小.
- 低AEs发病率 (13.43%),主要是轻度至中度,报告患者的3.73%.
结论:
- 在所有测量的PROM中,CBMP启动与改善HRQoL和一般福祉相关.
- 观察到的临床显著改善与现有的CBMP文献一致.
- CBMPs表现出良好的耐受性,尽管需要进一步的随机对照试验来确定因果关系.
相关概念视频
Pharmacovigilance
739
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
739
Clinical Trials: Overview
2.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.4K
Arteries of the Lower Limbs
166
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
166
Cancer Survival Analysis
298
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
298
Antiepileptic Drugs: Potassium Channel Activators
123
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
123


